Abstract
Purpose The present study evaluates the severity and time to resolution of bowel symptoms in men undergoing prostate brachytherapy (PB) with cesium-131 ( 131Cs). Methods and Materials A longitudinal, prospective study of patients who had undergone PB with 131Cs at a single institution was performed. All patients were asked to complete the Expanded Prostate Cancer Index Composite preoperatively and at 2 weeks and 1, 3, and 6 months postoperatively. Outcomes were analyzed using descriptive statistics and Student’s t test. Results The first 142 patients to have undergone PB with 131Cs at our institution were included in the study. The mean Expanded Prostate Cancer Index Composite bowel summary score at baseline was 90.1 ± 11.0 compared with 71.5 ± 22.8 ( p = 0.000), 70.1 ± 20.7, 87.1 ± 13.8 ( p = 0.01), and 90.7 ± 9.2 ( p = 0.70) at 2 weeks and 1, 3, and 6 months postoperatively, respectively. Conclusions In men undergoing PB as monotherapy with 131Cs, bowel symptoms returned to baseline by 3 months after the procedure. For patients undergoing PB with 131Cs as part of combination therapy, bowel symptoms return to their post–external beam radiotherapy, pre-PB baseline by 3 months after the procedure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.